A. Laurenza, et al., Molecular Pharmacology, 32, 133 (1987). |
CALBIOCHEM Biochemical/Immunochemical Catalog, 1988 New Product supplement, p. 18. |
S. P. Bartels, et al., Current Eye Research, 2, 673 (Feb. 1983). |
R. J. Cherill, et al., Abstracts of Papers, 192nd ACS National Meeting, Medi, No. 48 (Sep. 1986). |
J. Caprioli and M. Sears, The Yale Journal of Biology and Medicine, 57, 283 (1984). |
K. B. Seamon and J. W., Daly, Trends in Pharmacological Sciences, 48,120 (1983). |
K. B. Seamon and J. W. Daly, J., Cyclic Nucleotide Research, 7, 201 (1981). |
J. Caprioli, et al., Abstracts, Association for Research in Vision and Ophthalmology, 233 (1986). |
S. P. Bartels, et al., Current Eye Research, 6, 307 (1987). |
K. B. Seamon and J. W. Daly, in "Advances in Cyclic Nucleotide and Protein Phosphorylation Research", vol. 20, P. Greengard and G. A. Robison, Editors, Raven Press, New York, N.Y., 1986, pp. 1 to 150. |
N. J. de Sousa, et al., Medicinal Research Reviews, 3, 201 (1983). |
S. V. Bhat, et al., J. Med. Chem.,26,486 (1983). |
K. B. Seamon, et al., J. Med. Chem.,26, 436 (1983). |
S. V. Bhat, et al., Tetrahedron Letters, 1669 (1977). |
S. V. Bhat, et al., J. C. S. Perkin I, 767 (1982). |
J. Caprioli, et al., Investigative Ophthalmology and Visual Science, 25, 268 (1984). |
J. Caprioli and M. Sears, The Lancet, 958 (1983). |
K. B. Seamon, et al., Proc. Natl. Acad. Sci, USA 78, 3363 (1981). |
K. Seamon and J. W. Daly, The Journal of Biological Chemistry, 256, 9799(1981). |
J. Takeda, et al., The Journal of Investigative Dermatology, 81, 236 (1983). |
J. Takeda, et al., The Journal of Investigative Dermatology, 81, 131 (1983). |
H. Hzuka, et al., Biochimica et Biophysica Acta., 444, 685 (1976). |
H. Hzuka, et al., Biochimica et Biophysica Acta., 437,150 (1976). |
J. J. Voorhees, The Journal of Investigative Dermatology, 59, 114 (1972). |
K. M. Halprin, et al., The Journal of Investigative Dermatology, 65, 170 (1975). |
W. P. Raab, International Journal of Clinical Pharmacology, Therapy and Toxicology, 18, 212 (1980). |